Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05372354 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
260
Enrollment target
17
Study locations

NCT05372354 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (52% lower). The trial reports 17 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05372354, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
260 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Trametinib
  • DRUG Tazemetostat
  • DRUG CC-92480
  • DRUG BMS-986158

Study Locations (17)

Other

  • ICO - Hospital Germans Trias i Pujol - Barcelona
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Marques de Valdecilla - Santander
  • NIHR UCLH Clinical Research Facility - London

Alberta

  • Alberta Health Services AHS - Foothills Medical Centre FMC - Calgary
  • University of Alberta - Cross Cancer Institute - Edmonton

Alabama

  • UAB Comprehensive Cancer Center - Birmingham

Maryland

  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New Jersey

  • John Theurer Cancer Center at Hackensack UMC - Hackensack

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ontario

  • University Health Network UHN - Princess Margaret Hospital PMH - Toronto

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2022-10-18
Est. Completion 2026-10-12
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05372354

The ClinicalTrials.gov registry entry for NCT05372354 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (52% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT05372354 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Other, Alberta, Alabama.

Frequently Asked Questions

What is clinical trial NCT05372354 about?

NCT05372354 is a clinical study titled "A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

What is the current status of trial NCT05372354?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2022-10-18. Estimated completion is 2026-10-12.

What conditions does trial NCT05372354 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05372354?

The interventions under investigation include: Dexamethasone (DRUG), Trametinib (DRUG), Tazemetostat (DRUG), CC-92480 (DRUG), BMS-986158 (DRUG).

Who is sponsoring clinical trial NCT05372354?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05372354 being conducted?

This trial has 17 study locations across Alabama, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.